Jody Staggs

Jan 12, 2024 | lifescienceleader.com | Jody Staggs

By Jody Staggs The life sciences industry is characterized by innovation and groundbreaking discoveries that transform healthcare. However, securing funding remains challenging, particularly for companies in the early stages of clinical development. As we enter 2024, here are five considerations for companies navigating the life sciences financing landscape: Diversify Funding Sources In a challenging financing environment, having multiple options is key.

Oct 23, 2023 | outsourcedpharma.com | Peter Alexander |Phillip Ramsey |Jody Staggs |SWK Holdings |Louis Garguilo

We’ve all heard how important speed, time to milestone, and quality are when choosing a CTDMO. Our “Why choosing a client-centric CTDMO is critical when outsourcing biomanufacturing projects” infographic details the top five considerations and the complexities biopharma companies such as yours consider when selecting a CTDMO. Evaluate the infographic against your current challenges and share with us. We’re here. We’re built to serve. Download infographic.

Sep 27, 2023 | lifescienceleader.com | Jody Staggs |SWK Holdings

By Jody Staggs, president and CEO, SWK Holdings Small life science companies are the driving force behind groundbreaking medical innovations that have the potential to transform lives. Yet in a market with strong headwinds, securing financing has emerged as a central challenge. A sector once flush with cash is facing a liquidity crunch as the COVID-19 pandemic recedes from memory and capital markets are more discerning in funding the sector.

Sep 27, 2023 | outsourcedpharma.com | Jody Staggs |SWK Holdings |Louis Garguilo

Guest Column | September 27, 2023 By Jody Staggs, president and CEO, SWK Holdings Small life science companies are the driving force behind groundbreaking medical innovations that have the potential to transform lives. Yet in a market with strong headwinds, securing financing has emerged as a central challenge.

Jun 20, 2023 | bioprocessonline.com | Matthew Pillar |Richard Steiner |Jody Staggs

This month on the Business of Biotech podcast, everyone's favorite CFO, Allan Shaw, got pissed off — albeit in an eloquent New Yorker kind of way — about the unintended patient and biopharma industry consequences of the Inflation Reduction Act. Patients, he posits, will be the biggest losers. Ambrx CEO Dan O'Connor waxed "military philosophical" about the fortitude required of a biopharma leader. After captaining a Marine unit in Desert Storm, he'd know.